Coherus COMPLETE Support Services.
- Published in:
- 2018
- Publication type:
- Product Review
Works matching DE "COHERUS Biosciences Inc."
Results: 2
1
2
Udenyca, Second Biosimilar to Neulasta, FDA-Approved to Reduce Risk for Infection in Patients with Nonmyeloid Malignancies.
- Published in:
- Oncology Practice Management, 2018, v. 8, n. 12, p. 13
- Publication type:
- Article